Company intelligence / Profile preview

Fortis Securities

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Fortis Therapeutics is a clinical-stage immuno-oncology company focused on developing novel antibody-drug conjugates (ADCs) for the treatment of various cancers. The company's lead program, FOR46, targets CD46, a protein highly expressed in multiple myeloma and metastatic castration-resistant prostate cancer (mCRPC). By leveraging its proprietary ADC technology, Fortis aims to deliver potent cytotoxic payloads specifically to tumor cells while minimizing off-target effects. The company is backed by prominent life science investors and is advancing its pipeline through early-phase clinical trials to address significant unmet needs in oncology.

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugateMonoclonal antibodySmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Fortis Securities.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fortis Securities.

Explore the full profile